An Open-labeled, Randomized, Multicenter, Prospective, Parallel Group, Interventional Study to Demonstrate the Effectiveness of 24 Weeks Treatment With Vildagliptin 50mg Bid as Add on to Metformin 500 mg Bid Compared to Metformin up to 1000 mg Bid in Chinese Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Vildagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms VISION
- Sponsors Novartis Pharmaceuticals
- 13 Jun 2017 Results of subgroup analysis of VISION trial presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 09 Jun 2015 Primary endpoint (Proportion of glycosylated haemoglobin) has been met as per abstract published at 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.